WO2012061914A3 - Método e kit para diagnóstico de condições neuropsiquiátricas, método para avaliação de tratamentos de condições neuropsiquiátricas e método de identificação de fármacos potencialmente úteis no tratamento de condições neuropsiquiátricas. - Google Patents

Método e kit para diagnóstico de condições neuropsiquiátricas, método para avaliação de tratamentos de condições neuropsiquiátricas e método de identificação de fármacos potencialmente úteis no tratamento de condições neuropsiquiátricas. Download PDF

Info

Publication number
WO2012061914A3
WO2012061914A3 PCT/BR2011/000417 BR2011000417W WO2012061914A3 WO 2012061914 A3 WO2012061914 A3 WO 2012061914A3 BR 2011000417 W BR2011000417 W BR 2011000417W WO 2012061914 A3 WO2012061914 A3 WO 2012061914A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropsychiatric conditions
conditions
kit
diagnosing
potentially useful
Prior art date
Application number
PCT/BR2011/000417
Other languages
English (en)
French (fr)
Other versions
WO2012061914A2 (pt
Inventor
Mirian Akemi Furuie Hayashi
Rodrigo Affonseca Bressan
Vitor Marcelo SILVEIRA BUENO BRANDÃO DE OLIVEIRA
Ary Gadelha De Alencar Araripe Neto
Mauricio Ferreira Marcondes Machado
Original Assignee
Universidade Federal De São Paulo - Unifesp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal De São Paulo - Unifesp filed Critical Universidade Federal De São Paulo - Unifesp
Publication of WO2012061914A2 publication Critical patent/WO2012061914A2/pt
Publication of WO2012061914A3 publication Critical patent/WO2012061914A3/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A presente invenção está relacionada a um teste diagnóstico e um kit para realização deste teste, que são úteis para diagnóstico de condições neuropsiquiátricas, em especial no diagnóstico da esquizofrenia, baseado na atividade da enzima Ndel1. A presente invenção ainda proporciona um método para a avaliação da eficácia de tratamentos dessas condições, bem como a identificação de fármacos com potencial no tratamento dessas condições.
PCT/BR2011/000417 2010-11-09 2011-11-09 Método e kit para diagnóstico de condições neuropsiquiátricas, método para avaliação de tratamentos de condições neuropsiquiátricas e método de identificação de fármacos potencialmente úteis no tratamento de condições neuropsiquiátricas. WO2012061914A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI1004231-8 2010-11-09
BRPI1004231-8A BRPI1004231A2 (pt) 2010-11-09 2010-11-09 mÉtodo e kit para diagnàstico de condiÇÕes neuropsiquiÁtricas, mÉtodo para avaliaÇço de tratamentos de condiÇÕes neuropsiquiÁtricas e mÉtodo de identificaÇço de fÁrmacos potencialmente éteis no tratamento de condiÇÕes neuropsiquiÁtricas

Publications (2)

Publication Number Publication Date
WO2012061914A2 WO2012061914A2 (pt) 2012-05-18
WO2012061914A3 true WO2012061914A3 (pt) 2012-09-13

Family

ID=46051340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000417 WO2012061914A2 (pt) 2010-11-09 2011-11-09 Método e kit para diagnóstico de condições neuropsiquiátricas, método para avaliação de tratamentos de condições neuropsiquiátricas e método de identificação de fármacos potencialmente úteis no tratamento de condições neuropsiquiátricas.

Country Status (2)

Country Link
BR (1) BRPI1004231A2 (pt)
WO (1) WO2012061914A2 (pt)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048236A1 (es) * 2002-11-22 2004-06-10 MULET VALLÉS, Tomás Máquina alimentadora-dispensadora de recipientes y artículos alargados en general.
WO2004053052A2 (en) * 2002-12-09 2004-06-24 Camargo Antonio HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA)
WO2009118151A1 (de) * 2008-03-26 2009-10-01 Carsten Korth Verfahren zur diagnose und behandlung von chronisch psychiatrischen erkrankungen sowie marker und targets für solche verfahren
WO2009138988A1 (en) * 2008-05-14 2009-11-19 Yeda Research And Development Co. Ltd. Compositions for modulating the activity of cytoplasmic dynein and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048236A1 (es) * 2002-11-22 2004-06-10 MULET VALLÉS, Tomás Máquina alimentadora-dispensadora de recipientes y artículos alargados en general.
WO2004053052A2 (en) * 2002-12-09 2004-06-24 Camargo Antonio HUMAN RECOMBINANT ENDOOLIGOPEPTIDASE A (hEOPA)
WO2009118151A1 (de) * 2008-03-26 2009-10-01 Carsten Korth Verfahren zur diagnose und behandlung von chronisch psychiatrischen erkrankungen sowie marker und targets für solche verfahren
WO2009138988A1 (en) * 2008-05-14 2009-11-19 Yeda Research And Development Co. Ltd. Compositions for modulating the activity of cytoplasmic dynein and methods of using same

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRADSHAW N. ET AL.: "DISC1-binding proteins in neural development, signalling and schizophrenia.", NEUROPHARMACOLOGY., vol. 62, 2012, pages 1230 AND 1241. *
BURDICK K.E. ET AL.: "Elucidating. the relationship between DISC1, NDEL1 and NDE1 and the risk for schizophrenia: Evidence of epistasis and competitive binding.", HUM. MOL. GENET.., vol. 17, no. 16, 2008, pages 2462 AND 2473 *
HAYASHI M.A.F. ET AL.: "Assessing the role of endooligopeptidase activity of Ndell (nuclear-distribution gene E homolog like-1) in neurite outgrowth.", MOL. CELL. NEUROSCI., 2010, pages 353 A 361 *
HAYASHI M.A.F. ET AL.: "Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1.", PROC NATL ACAD SCI U S A., vol. 102, no. 10, pages 3828 A 3833 *
HAYASHI M.A.F. ET AL.: "Molecular and Immunochemical Evidences Demonstrate That Endooligopeptidase A Is the Predominant Cytosolic Oligopeptidase of Rabbit Brain.", BIOCHEM BIOPHYS RES COMMUN., vol. 269, 2000, pages 7 - 13 *
LIPSKA B.K. ET AL.: "Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs.", HUM. MOL. GENET., vol. 15, no. 8, 2006, pages 1245 A 1258 *
TOMPPO L. ET AL.: "Association Between Genes of Disrupted in Schizophrenia 1 (DISC1) Interactors and Schizophrenia Supports the Role of the DISCI Pathway in the Etiology of Major Mental Illnesses.", BIOL. PSYCHIATRY., vol. 65, 2009, pages 1055 AND 1062 *

Also Published As

Publication number Publication date
WO2012061914A2 (pt) 2012-05-18
BRPI1004231A2 (pt) 2013-03-12

Similar Documents

Publication Publication Date Title
WO2013063155A3 (en) Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP3355057A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
EP3486657A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
IL222252A (en) A system, device and method for detecting and diagnosing biological arrhythmias
WO2010032059A3 (en) Antibodies directed to cd105 and uses thereof
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2011137320A3 (en) Small molecule inhibitors of usp1 deubiquitinating enzyme activity
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
EA201590630A1 (ru) Способы лечения и диагностики, связанные с лизилоксидазоподобным белком 2 (loxl2)
WO2014133855A8 (en) Tuberculosis biomarkers and uses thereof
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2010072740A3 (en) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010119126A3 (en) Diagnostic methods and tools to predict the efficacy of targeted agents against igf-1 pathway activation in cancer
WO2011106785A3 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2009120712A3 (en) Compositions and methods for diagnosing and treating melanoma
MY155340A (en) Use of cathepsin c
MY154715A (en) Anti-nr10 antibody and use thereof
WO2012004276A3 (en) Multiprotein biomarkers of amyotrophic lateral sclerosis in peripheral blood mononuclear cells, diagnostic methods and kits
WO2012074882A3 (en) Phagocytic activity as a marker of synucleinopathic disease
WO2009023846A3 (en) Methods for heat shock protein dependent cancer treatment
WO2014008273A3 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states
WO2008067351A3 (en) Method of diagnosing and treating glioma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840351

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11840351

Country of ref document: EP

Kind code of ref document: A2